Ioannis V Kostopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7732736/publications.pdf

Version: 2024-02-01

		686830	752256
53	552	13	20
papers	citations	h-index	g-index
			206
55	55	55	926
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal, 2018, 8, 46.	2.8	39
2	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Advances, 2019, 3, 3002-3009.	2.5	37
3	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Frontiers in Oncology, 2020, 10, 860.	1.3	35
4	Immunogenic Cell Death, DAMPs and Prothymosin \hat{l}_\pm as a Putative Anticancer Immune Response Biomarker. Cells, 2022, 11, 1415.	1.8	34
5	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life, 2020, 10, 214.	1.1	31
6	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses, 2021, 13, 26.	1.5	26
7	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers, 2020, 12, 3245.	1.7	24
8	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 19-23.	1.4	22
9	ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): The spectrum of clonal heterogeneity and its impact on prognosis. Cancer Genetics, 2018, 224-225, 1-11.	0.2	20
10	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. HemaSphere, 2019, 3, e300.	1.2	20
11	The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica, 2022, 107, 721-732.	1.7	17
12	Automated detection and classification of nuclei in PAX5 and H& E-stained tissue sections of follicular lymphoma. Signal, Image and Video Processing, 2017, 11, 145-153.	1.7	16
13	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers, 2020, 12, 2006.	1.7	15
14	Daratumumabâ€based therapy for patients with monoclonal gammopathy of renal significance. British Journal of Haematology, 2021, 193, 113-118.	1.2	15
15	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood, 2022, 139, 1939-1953.	0.6	15
16	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms, 2021, 9, 546.	1.6	14
17	Acute administration of the olive constituent, oleuropein, combined with ischemic postconditioning increases myocardial protection by modulating oxidative defense. Free Radical Biology and Medicine, 2021, 166, 18-32.	1.3	14
18	Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of Bâ€acute lymphoblastic leukemia. International Journal of Laboratory Hematology, 2019, 41, 364-372.	0.7	12

#	Article	IF	CITATIONS
19	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines, 2021, 9, 207.	2.1	12
20	Using adaptive neuro-fuzzy inference systems for the detection of centroblasts in microscopic images of follicular lymphoma. Signal, Image and Video Processing, 2014, 8, 33-40.	1.7	11
21	Immunophenotypic analysis reveals heterogeneity and common biologic aspects in monoclonal Bâ€cell lymphocytosis. Genes Chromosomes and Cancer, 2015, 54, 210-221.	1.5	11
22	Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 273-285.	1.0	11
23	Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. Cancers, 2019, 11, 1764.	1.7	10
24	An extended fluorescence in situ hybridization approach for the cytogenetic study of cholangiocarcinoma on endoscopic retrograde cholangiopancreatography brushing cytology preparations. Human Pathology, 2013, 44, 2173-2179.	1.1	9
25	Heart and lymphoma: An unusual case of secondary cardiac lymphoma manifested through presyncope and syncope episodes and atrial flutter. Hellenic Journal of Cardiology, 2018, 59, 182-185.	0.4	9
26	Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2017, 7, e597-e597.	2.8	8
27	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers, 2021, 13, 4047.	1.7	8
28	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 259-266.	1.4	8
29	The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells. Biomedicines, 2022, 10, 209.	1.4	8
30	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, doubleâ€hit highâ€grade Bâ€cell lymphoma, and singleâ€hit MYC â€rearranged diffuse large Bâ€cell lymphoma. Cytometry Part B - Clinical Cytometry, 2020, 98, 412-420.	0.7	7
31	Cytotoxicity and Anti-cancer Activity of the Genus Achillea L Current Medicinal Chemistry, 2020, 27, 6910-6925.	1.2	7
32	Clinical presentation, diagnosis, and survival in cholangiocarcinoma: A prospective study. Arab Journal of Gastroenterology, 2016, 17, 181-184.	0.4	5
33	Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients. Blood, 2019, 134, 4338-4338.	0.6	4
34	FISH Image Analysis Using a Modified Radial Basis Function Network. , 2007, , .		3
35	Evidence for neoangiogenesis in the ischemic human heart after mechanical support and autologous bone marrow stem cell implantation. Journal of Heart and Lung Transplantation, 2015, 34, 1208-1210.	0.3	3
36	Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential. Heliyon, 2019, 5, e02616.	1.4	3

#	Article	IF	Citations
37	Expression of the activation markers Blimp1, Foxp1 and pStat3 in extranodal diffuse large B-cell lymphomas. Histology and Histopathology, 2017, 32, 825-834.	0.5	3
38	Familial chronic lymphocytic leukemia in two siblings with ATM/13q14 deletion and a similar pattern of clonal evolution. Blood Cancer Journal, 2015, 5, e322-e322.	2.8	1
39	Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology. Blood, 2019, 134, 3783-3783.	0.6	1
40	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma. Leukemia and Lymphoma, 2022, 63, 551-561.	0.6	1
41	Prothymosin $\hat{I}\pm$ and Its C-Terminal Immunoreactive Decapeptide Show no Evidence of Acute Toxicity: A Preliminary in Silico, in Vitro and in Vivo Investigation. Current Medicinal Chemistry, 2021, 28, .	1.2	1
42	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. Blood, 2020, 136, 25-25.	0.6	1
43	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S331-S332.	0.2	0
44	Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e184-e185.	0.2	0
45	Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e185-e186.	0.2	0
46	MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S297-S298.	0.2	0
47	MM-252: Aberrant Plasma Cells in the Apheresis Product as a Prognostic Factor for Minimal Residual Disease Negativity After Transplant in Newly Diagnosed Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S305.	0.2	0
48	MM-408: The Assessment of Stem Cell Graft Contamination via Next-Generation Flow Cytometry Serves as a Negative Predictor for Deep Remissions Post-Autologous Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S441.	0.2	0
49	INK4 Locus Deletion in Childhood Acute Lymphoblastic Leukemia (ChALL)-a Preliminary Clinical Evaluation. Blood, 2008, 112, 4858-4858.	0.6	0
50	Clonal Heterogeneity in TEL/AML1+ Acute Lymphoblastic Leukemia (ALL): A Clinical Appraisal. Blood, 2008, 112, 3942-3942.	0.6	0
51	PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup. Blood, 2019, 134, 3760-3760.	0.6	0
52	Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes. Blood, 2019, 134, 2521-2521.	0.6	0
53	4th Summer School in Immuno-Oncology, July 1st–3rd, 2021, Athens, Greece. Frontiers in Bioscience, 2021, 26, 1373.	0.8	0